Table 1.
Advances in vaccination against leishmaniasis.
| Vaccine Candidate | Type of Vaccine | Quality of Protection/Species | Host | Reference(s) |
|---|---|---|---|---|
| CaniLeish® | Fractionated | Good | Dogs | [98] |
| Leishmune® | Fractionated | Good | Dogs | [98,99] |
| LiESP/QA-21 | Good | Dogs | [100] | |
| LetiFend® | Recombinant protein | Good/L. infantum | Dogs | [101] |
| ES LaPSA-38S | Recombinant protein | Good prophylactic vaccine | Dogs | [102] |
| LBSap vaccine (L. brazilliensis antigen & saponin adjuvant) | Fractionated | Good/cross-protection (L. infantum) | Dogs | [103] |
| LbSapSal vaccine (L. brazilliensis antigen + saponin + lutzomiyia longpalpis salivary gland extract) | Fractionated | Good/cross protection (L. chagasi) | Dogs | [104] |
| Leishmania glycosomal PEPCK | Recombinant protein | Good/cross protection (L. major, L. donovani) | Mice | [105,106] |
| Promastigote Surface Antigen (PSA) from L. amazonensis | Recombinant protein | Good/L. amazonensis | Human T cells | [107] |
| ChAd63-KH | DNA | Good/L. donovani | Human (Clinical trial) | [108] |
| L. bralizilliensis antigen + monophosphoryl lipid A (MPL) adjuvant | Subunit | Good/L. infantum | Dogs | [109] |